Core Insights - VIO Med Spa has been selected as a key franchise partner for Obagi Medical's Aesthetics Leadership with Obagi's Hyaluronic Acid (ALOHA) Program due to its commitment to clinical excellence and innovative aesthetic care [1][4] - The partnership aims to leverage VIO Med Spa's strengths in injectables and patient education to generate real-world evidence on the performance of Obagi® saypha® MagIQ™ filler [2][3] Company Overview - Obagi Medical is a leading innovator in physician-dispensed skincare with over 35 years of experience, known for addressing various skin concerns and recognized as the fastest-growing professional skincare brand in the U.S. in 2024 [6][10] - VIO Med Spa is a nationally recognized franchise specializing in advanced aesthetic and wellness treatments, focusing on clinical excellence and patient safety across its numerous locations [7] Program Details - The ALOHA Program will conduct a structured, multi-site assessment of the filler, emphasizing both clinical performance and patient experience while providing comprehensive protocols to enhance satisfaction and outcomes [3][4] - The program will kick off with a two-day immersive training for the VIO network, aimed at standardizing data collection across participating locations [3]

Alpha selected as the first Medspa platform partner given their commitment to innovation, education, and breaking through barriersNEW YORK and SACRAMENTO, Calif., Jan. 27, 2026 (GLOBE NEWSWIRE) -- Obagi Medical, a leading innovator in physician-dispensed skincare and aesthetic solutions and part of Waldencast plc (NASDAQ: WALD) (“Waldencast” or the “Company”), today announced that it has partnered with Alpha Aesthetic Partners for the Aesthetics Leadership with Obagi‘s Hyaluronic Acid (ALOHA) Program. Alpha ...